BCAL Diagnostics (ASX:BDX) Other Current Receivables: A$0.00 Mil (As of Dec. 2025)


What is BCAL Diagnostics Other Current Receivables?

BCAL Diagnostics ASX:BDX +1.39% Other Current Receivables is A$0.00 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

BCAL Diagnostics's Other Current Receivables for the quarter that ended in Dec. 2025 was A$0.00 Mil.

BCAL Diagnostics's annual Other Current Receivables increased from Jun. 2023 (A$0.00 Mil) to Jun. 2024 (A$0.04 Mil) but then declined from Jun. 2024 (A$0.04 Mil) to Jun. 2025 (A$0.01 Mil).

BCAL Diagnostics Other Current Receivables Related Terms

BCAL Diagnostics Other Current Receivables Historical Data

* Premium members only.

The historical data trend for BCAL Diagnostics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BCAL Diagnostics Other Current Receivables Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Other Current Receivables
0.01 0.00 0.04 0.01

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.04 0.00 0.01 0.00

BCAL Diagnostics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of A$0.00 Mil mean?
BCAL Diagnostics (ASX:BDX) has a Other Current Receivables of A$0.00 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on BCAL Diagnostics and its competitors.
Is BCAL Diagnostics' Other Current Receivables too high?
BCAL Diagnostics' current Other Current Receivables is A$0.00 Mil.
How does BCAL Diagnostics' Other Current Receivables compare to TMO and DHR?
BCAL Diagnostics' Other Current Receivables of A$0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Medical Diagnostics & Research company?
A good Other Current Receivables depends on the Medical Diagnostics & Research industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on BCAL Diagnostics and its competitors. BCAL Diagnostics's current Other Current Receivables is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current Other Current Receivables of A$0.00 Mil. The current Other Current Receivables is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current Other Current Receivables is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BCAL Diagnostics Business Description

Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.